| abstract |
Disclosed is a method of treating inflammatory, precancerous or cancerous tissue or polyps in a mammalian subject. The treatment includes administering a composition of at least one peptide agonist of the guanylate cyclase receptor and / or other small molecules that increase intracellular production of cGMP. This at least one peptide agonist of the guanylate cyclase receptor can be administered alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The inhibitor may be a small molecule, peptide, protein, or other compound that inhibits cGMP degradation. Without the need for a specific mechanism of action, this treatment can also restore a healthy balance between proliferation and apoptosis of the epithelial cells in the test population and suppress carcinogenesis. Thus, this method is used specifically to treat intestinal inflammatory disorders, inflammation including systemic organ inflammation and asthma, and lung, gastrointestinal tract, bladder, testis, prostate and pancreatic carcinogenesis, or polyps, among others. be able to. [Selection figure] None |